FTY720 protects retinal ganglion cells in experimental glaucoma

Area of Science:

• Ophthalmology
• Neuroscience
• Pharmacology

Background:

• Glaucoma is a leading cause of irreversible blindness characterized by progressive optic nerve damage.
• Retinal ganglion cells (RGCs) are crucial for visual processing and are selectively vulnerable in glaucoma.
• Sphingosine-1-phosphate (S1P) signaling pathways are implicated in neuronal survival and inflammation.

Purpose of the Study:

• To evaluate the neuroprotective potential of fingolimod (FTY720), an S1P analogue, in a rat model of experimental glaucoma.
• To assess the impact of FTY720 on retinal ganglion cell survival and optic nerve integrity.
• To investigate the underlying molecular mechanisms, including Akt and Erk1/2 signaling, and S1P receptor expression.

Main Methods:

• A chronic ocular hypertensive glaucoma model was induced in rats using microbead injections.
• Fingolimod (FTY720) was administered intraperitoneally weekly for 3 months.
• Functional RGC assessment via scotopic threshold response (STR), histological evaluation of GCL and optic nerve, and Western blot analysis for signaling pathways and S1P receptors.

Main Results:

• FTY720 treatment significantly preserved STR amplitude, indicating functional RGC protection.
• Histological analysis revealed significant preservation of GCL cell density and optic nerve axonal count in FTY720-treated rats.
• FTY720 administration increased phosphorylation of Akt and Erk1/2, and S1P1 and S1P5 receptors were expressed in the retina, with S1P1R upregulated in glaucoma.

Conclusions:

• Fingolimod (FTY720) exhibits significant neuroprotective effects against structural and functional loss in experimental glaucoma.
• FTY720 preserves retinal ganglion cells and optic nerve integrity, suggesting its potential as a therapeutic agent for glaucoma.
• The findings highlight the role of S1P signaling in neuroprotection and provide a basis for further clinical investigation.